News

Two-year Outcomes of the FAVOR III China Trial

Dr. Lei Song from Fuwai hospital, Beijing, China, and many co-authors under the supervision of Dr. Greg Stone, presented these 2-year FU data at the TCT 2022, and the results are accepted for publication in JACC.

This is the 2-year FU of the FAVOR III China trial, in which eligible patients were randomized to a QFR®-guided strategy or a standard angiography-guided strategy. Among the 3825 randomized participants, the 2-year MACE occurred in 8.5% in the QFR®-guided group and 12.5% in the angiography-guided group, a difference of 32% in favor of the QFR®-guided group. The benefits were most pronounced among patients in whom QFR® assessment altered the planned revascularization strategy.

Please see the attached report for a complete overview of this study.

If you would like to read this article: JACC 2022; Angiographic Quantitative Flow Ratio-Guided Coronary Intervention: Angiographic Quantitative Flow Ratio-Guided Coronary Intervention: Two-Year Outcomes of the FAVOR III China Trial – ScienceDirect

Share this article on:

LinkedIn
Twitter

Do you want to learn more about QFR®?

Check out the product page of Medis QFR®, to learn more. If you have any other questions, feel free to reach out to us.

Sign up for our newsletter

Subscribe now to find out more about our solutions, latest publications and future releases.

By providing your information and continuing, you agree to Medis’ Terms of Use and Privacy Policy *